KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Cost of Revenue (2016 - 2025)

Biogen (BIIB) has 17 years of Cost of Revenue data on record, last reported at $495.5 million in Q4 2025.

  • For Q4 2025, Cost of Revenue fell 15.08% year-over-year to $495.5 million; the TTM value through Dec 2025 reached $2.4 billion, up 4.06%, while the annual FY2025 figure was $2.4 billion, 4.06% up from the prior year.
  • Cost of Revenue reached $495.5 million in Q4 2025 per BIIB's latest filing, down from $674.4 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $962.9 million in Q2 2022 and bottomed at $275.0 million in Q1 2022.
  • Average Cost of Revenue over 5 years is $581.8 million, with a median of $588.1 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: crashed 42.48% in 2022, then surged 141.02% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $660.1 million in 2021, then decreased by 13.51% to $570.9 million in 2022, then rose by 8.3% to $618.3 million in 2023, then dropped by 5.63% to $583.5 million in 2024, then fell by 15.08% to $495.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $495.5 million in Q4 2025, $674.4 million in Q3 2025, and $605.0 million in Q2 2025.